[Sequential combination of high-dose cytosine arabinoside and L-asparaginase in the treatment of refractory acute leukemia and malignant lymphoma]. 1985

C Shimazaki, and N Fujita, and S Nakanishi, and A Nishio, and H Haruyama, and M Nakagawa, and H Ijichi

Clinical effects of sequential administration of high-dose cytosine arabinoside with L-asparaginase were studied in 5 cases of refractory acute leukemia and 2 cases of non-Hodgkin's lymphoma. A total 12 courses were carried out on these 7 patients and complete remission was obtained in 2 courses and partial remission in 3 courses. Two cases of lymphoma with pleural effusion or CNS invasion achieved partial and complete remission, respectively. The side effects associated with this sequential therapy were nausea, vomiting, diarrhea, fever and conjunctivitis, although these were tolerable. These observations suggest that high-dose cytosine arabinoside combined with L-asparaginase is a useful regimen for refractory leukemia and lymphoma.

UI MeSH Term Description Entries
D007945 Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts. Leukemia, Lymphocytic,Lymphocytic Leukemia,Lymphoid Leukemia,Leukemias, Lymphocytic,Leukemias, Lymphoid,Lymphocytic Leukemias,Lymphoid Leukemias
D008223 Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. Germinoblastoma,Lymphoma, Malignant,Reticulolymphosarcoma,Sarcoma, Germinoblastic,Germinoblastic Sarcoma,Germinoblastic Sarcomas,Germinoblastomas,Lymphomas,Lymphomas, Malignant,Malignant Lymphoma,Malignant Lymphomas,Reticulolymphosarcomas,Sarcomas, Germinoblastic
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

C Shimazaki, and N Fujita, and S Nakanishi, and A Nishio, and H Haruyama, and M Nakagawa, and H Ijichi
January 1982, Medical and pediatric oncology,
C Shimazaki, and N Fujita, and S Nakanishi, and A Nishio, and H Haruyama, and M Nakagawa, and H Ijichi
July 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
C Shimazaki, and N Fujita, and S Nakanishi, and A Nishio, and H Haruyama, and M Nakagawa, and H Ijichi
June 1985, Seminars in oncology,
C Shimazaki, and N Fujita, and S Nakanishi, and A Nishio, and H Haruyama, and M Nakagawa, and H Ijichi
January 1987, Sangre,
C Shimazaki, and N Fujita, and S Nakanishi, and A Nishio, and H Haruyama, and M Nakagawa, and H Ijichi
April 1998, Medical and pediatric oncology,
C Shimazaki, and N Fujita, and S Nakanishi, and A Nishio, and H Haruyama, and M Nakagawa, and H Ijichi
June 1987, Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association,
C Shimazaki, and N Fujita, and S Nakanishi, and A Nishio, and H Haruyama, and M Nakagawa, and H Ijichi
February 1985, Gan to kagaku ryoho. Cancer & chemotherapy,
C Shimazaki, and N Fujita, and S Nakanishi, and A Nishio, and H Haruyama, and M Nakagawa, and H Ijichi
October 1979, Cancer,
C Shimazaki, and N Fujita, and S Nakanishi, and A Nishio, and H Haruyama, and M Nakagawa, and H Ijichi
December 1984, [Rinsho ketsueki] The Japanese journal of clinical hematology,
C Shimazaki, and N Fujita, and S Nakanishi, and A Nishio, and H Haruyama, and M Nakagawa, and H Ijichi
January 1985, Sangre,
Copied contents to your clipboard!